Your browser doesn't support javascript.
loading
Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
Lee, Leo Yi Yang; Zhou, Jie; Frise, Rebecca; Goldhill, Daniel H; Koszalka, Paulina; Mifsud, Edin J; Baba, Kaoru; Noda, Takahiro; Ando, Yoshinori; Sato, Kenji; Yuki, Aoe-Ishikawa; Shishido, Takao; Uehara, Takeki; Wildum, Steffen; Zwanziger, Elke; Collinson, Neil; Kuhlbusch, Klaus; Clinch, Barry; Hurt, Aeron C; Barclay, Wendy S.
Afiliação
  • Lee LYY; WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Zhou J; Department of Infectious Disease, Imperial College London, London, United Kingdom.
  • Frise R; Department of Infectious Disease, Imperial College London, London, United Kingdom.
  • Goldhill DH; Department of Infectious Disease, Imperial College London, London, United Kingdom.
  • Koszalka P; WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Mifsud EJ; Biomedicine Discovery Institute & Department of Microbiology, Monash University, Victoria 3800, Australia.
  • Baba K; WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Noda T; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Australia.
  • Ando Y; Shionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan.
  • Sato K; Shionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan.
  • Yuki AI; Shionogi & Co., Ltd, Osaka, Japan.
  • Shishido T; Shionogi & Co., Ltd, Osaka, Japan.
  • Uehara T; Shionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan.
  • Wildum S; Shionogi & Co., Ltd, Osaka, Japan.
  • Zwanziger E; Shionogi & Co., Ltd, Osaka, Japan.
  • Collinson N; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Kuhlbusch K; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Clinch B; Roche Products Ltd, Welwyn, United Kingdom.
  • Hurt AC; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Barclay WS; Roche Products Ltd, Welwyn, United Kingdom.
PLoS Pathog ; 16(4): e1008395, 2020 04.
Article em En | MEDLINE | ID: mdl-32294137
ABSTRACT
Influenza viruses cause seasonal outbreaks and pose a continuous pandemic threat. Although vaccines are available for influenza control, their efficacy varies each season and a vaccine for a novel pandemic virus manufactured using current technology will not be available fast enough to mitigate the effect of the first pandemic wave. Antivirals can be effective against many different influenza viruses but have not thus far been used extensively for outbreak control. Baloxavir, a recently licensed antiviral drug that targets the influenza virus endonuclease, has been shown to reduce virus shedding more effectively than oseltamivir, a widely used neuraminidase inhibitor drug. Thus it is possible that treatment with baloxavir might also interrupt onward virus transmission. To test this, we utilized the ferret model, which is the most commonly used animal model to study influenza virus transmission. We established a subcutaneous baloxavir administration method in ferrets which achieved similar pharmacokinetics to the approved human oral dose. Transmission studies were then conducted in two different locations with different experimental setups to compare the onward transmission of A(H1N1)pdm09 virus from infected ferrets treated with baloxavir, oseltamivir or placebo to naïve sentinel ferrets exposed either indirectly in adjacent cages or directly by co-housing. We found that baloxavir treatment reduced infectious viral shedding in the upper respiratory tract of ferrets compared to placebo, and reduced the frequency of transmission amongst sentinels in both experimental setups, even when treatment was delayed until 2 days post-infection. In contrast, oseltamivir treatment did not substantially affect viral shedding or transmission compared to placebo. We did not detect the emergence of baloxavir-resistant variants in treated animals or in untreated sentinels. Our results support the concept that antivirals which decrease viral shedding could also reduce influenza transmission in the community.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Oxazinas / Piridinas / Tiepinas / Triazinas / Replicação Viral / Eliminação de Partículas Virais / Infecções por Orthomyxoviridae / Vírus da Influenza A Subtipo H1N1 / Neuraminidase Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Oxazinas / Piridinas / Tiepinas / Triazinas / Replicação Viral / Eliminação de Partículas Virais / Infecções por Orthomyxoviridae / Vírus da Influenza A Subtipo H1N1 / Neuraminidase Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article